Bayer AG announced Wednesday it is raising its full-year 2025 financial guidance following better-than-expected performance in its Pharmaceuticals division during the first half of the year.
The company now expects to post Group sales of 46 to 48 billion euros, up from its previous forecast of 45 to 47 billion euros. Bayer also raised its projection for EBITDA before special items to 9.7 to 10.2 billion euros and increased its guidance for currency-adjusted core earnings per share to 4.80 to 5.30 euros.
For the Pharmaceuticals Division, Bayer now anticipates currency- and portfolio-adjusted sales growth of 0 to 3 percent, a significant improvement from its previous forecast of minus 4 to minus 1 percent.
In the second quarter of 2025, Bayer generated approximately 10.7 billion euros in Group sales. The Crop Science Division increased sales by 2.2 percent on a currency- and portfolio-adjusted basis, while Pharmaceuticals and Consumer Health divisions maintained prior-year sales levels.
The company also provided updates on its U.S. litigation, establishing additional provisions of around 1.2 billion euros for Roundup cases. Bayer reported progress in its settlement strategy, reducing the total number of unresolved glyphosate claims to 61,000 out of 192,000 total claims.
For PCB litigation, Bayer recorded 530 million euros in additional provisions related to the Burke case and potential future settlements involving the Sky Valley Education Center in Washington state.
Bayer will publish detailed results for the second quarter on August 6, 2025.
